SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001213900-24-098322
Filing Date
2024-11-14
Accepted
2024-11-14 15:30:59
Documents
1
Group Members
GUY LEVYSOLEUS CAPITAL GROUP, LLCSOLEUS CAPITAL MANAGEMENT, L.P.SOLEUS CAPITAL, LLCSOLEUS GP, LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO SCHEDULE 13G ea0221047-13ga1soleus_terns.htm SC 13G/A 141816
  Complete submission text file 0001213900-24-098322.txt   143616
Mailing Address 104 FIELD POINT ROAD 2ND FLOOR GREENWICH CT 06830
Business Address 104 FIELD POINT ROAD 2ND FLOOR GREENWICH CT 06830 4752083111
Soleus Capital Master Fund, L.P. (Filed by) CIK: 0001812275 (see all company filings)

IRS No.: 981413657 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404
Business Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 650-525-5535 EXT.101
Terns Pharmaceuticals, Inc. (Subject) CIK: 0001831363 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-92116 | Film No.: 241461029
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)